Services on Demand
Journal
Article
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Gaceta mexicana de oncología
On-line version ISSN 2565-005XPrint version ISSN 1665-9201
Abstract
BORNSTEIN-QUEVEDO, Leticia et al. Identification of NTRK fusion genes. Experience in Mexico. Gac. mex. oncol. [online]. 2023, vol.22, n.3, pp.107-113. Epub Sep 29, 2023. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.23000113.
Objective:
To assess the prevalence of TRK fusions in cancer patients in Mexico.
Material and methods:
In a basket study, the presence of NTRK fusion genes was determined by immunohistochemistry and next-generation sequencing in patients with various neoplasms.
Results:
A total of 677 patients were evaluated. The most frequent cancer types were central nervous system cancer (CNS) (15.1%), lung cancer (14.8%), sarcoma (14.6%) and digestive tube cancer (12.1%). NTRK fusion genes were detected in 4% of the total samples, and in 12.12% of pediatric samples. The most frequent fusions were BTCR-NTRK2 (22.2%), ETV6-NTRK (18.5%), and BCAN-NTRK-1, LMNA-NTRK1, TPM3-NTRK1 and 1AP-NTRK2 (7.4% each). CNS cancer presented the highest frequency (77.8%) of NTRK fusion genes.
Conclusions:
4% of the patients evaluated presented NTRK fusion genes, and most of them had CNS cancer. These patients could benefit from TRK inhibitors therapy.
Keywords : Oncogenic fusion; NTRK; Nervous system; Cancer; New generation sequencing; Immunohistochemistry.
